

Curriculum Vitae Europass



Informazioni personali

Cognome e Nome

Verzoni Elena

Data di nascita

INCARICO E STRUTTURA

Dirigente medico I livello
Medicina Oncologica, SSD. Oncologia Genitourinaria,
Fondazione IRCCS Istituto Nazionale dei Tumori
Milano

Esperienza professionale

Date	Dal 1 aprile 2015 ad oggi
Nome e indirizzo del datore di lavoro	Medicina Oncologica 1 (direttore Prof.F De Braud) Istituto Nazionale Fondazione IRCCS per lo Studio e la Cura dei Tumori, via Venezian 1, 20133, Milano
Lavoro o posizione ricoperti	Medico chirurgo, Specialista in Oncologia Medica, Dirigente Medico a tempo indeterminato
Principali attività e responsabilità	Gestione clinica ambulatoriale e di reparto di pazienti affetti da neoplasie solide, con particolare riferimento ai tumori del tratto genitourinario. Attività di ricerca clinica. Attività di guardia e reperibilità.
Dal 1 aprile 2011 al 31 marzo 2015	
Divisione di Oncologia Medica 1 Istituto Nazionale Fondazione IRCCS per lo Studio e la Cura dei Tumori, via Venezian 1 20133, Milano	
Medico chirurgo, Specialista in Oncologia Medica, Dirigente Medico a tempo determinato	
Gestione clinica ambulatoriale e di reparto di pazienti affetti da neoplasie solide. Attività di ricerca clinica.	

Dal novembre 2003 a ottobre 2007

Divisione di Oncologia Medica 2 (direttore Prof Emilio Bajetta)
Istituto Nazionale Fondazione IRCCS per lo Studio e la Cura dei Tumori, via Venezian 1
20133, Milano
Istituto per la cura e la ricerca
Medico chirurgo, specializzanda in Oncologia Medica
Gestione clinica ambulatoriale e di reparto di pazienti affetti da neoplasie solide.
Attività di ricerca clinica.

Da luglio 2003 a settembre 2003

Divisione di Oncologia Medica 2,
Istituto Nazionale Fondazione IRCCS per lo Studio e la Cura dei Tumori, via Venezian 1
20133, Milano
Unità operativa di Pronto Soccorso della Clinica San Giuseppe di Milano
Studente frequentatore-tirocinio pre-laurea

Da ottobre 2001 a giugno 2003

Divisione di Oncologia Medica 2
Istituto Nazionale Fondazione IRCCS per lo Studio e la Cura dei Tumori, via Venezian 1
20133, Milano
Istituto per la cura e la ricerca
Studente frequentatore

Da marzo 2000 a luglio 2000

Divisione di Cardiologia Clinica (dirett. Prof. Guazzi)
Centro Cardiologico Monzino IRCCS, Milano
Istituto per la cura e la ricerca
Studente frequentatore

Da novembre 1999 a febbraio 2000

Divisione di Chirurgia Generale (dirett. Prof. E.Contessini Avesani)
Ospedale Maggiore IRCCS, Milano
Istituto per la cura e la ricerca
Studente frequentatore

Istruzione e formazione

Date
Nome e tipo d'organizzazione erogatrice
dell'istruzione e formazione

9 Ottobre 2010 (35 ESMO Congress)**ESMO (European Society for Medical Oncology)**

Titolo della qualifica rilasciata **ESMO examination certificate**

Date ***Dal novembre 2003 a ottobre 2007***

Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione
Università degli Studi di Milano
Facoltà di Medicina e Chirurgia
Scuola di Specializzazione in Oncologia Medica

Principali tematiche/competenza professionali possedute	Tesi di specialità: “ Sorafenib nel carcinoma renale metastatico: esperienza dell’Istituto Nazionale per lo Studio e la Cura dei Tumori”
Titolo della qualifica rilasciata	Specializzazione in Oncologia Medica

Novembre 2006

VII Congresso Nazionale AIOM (Associazione Italiana Oncologia Medica)

AIOM Best Abstract 2006: “A phase III randomized study with Sorafenib in patients with advanced renal cell cancer”

Gennaio 2004 (II sessione anno accademico 2003-2004)

Università degli Studi di Milano

Facoltà di Medicina e Chirurgia

Abilitazione all’esercizio della professione di medico chirurgo

Dal novembre 1996 a ottobre 2003

Università degli Studi di Milano

Facoltà di Medicina e Chirurgia

Tesi di laurea: “Il Carcinoma mammario in fase avanzata nelle pazienti anziane: nuovi approcci con le fluoropirimidine orali”

Laurea in Medicina e Chirurgia

Dal 1991 al 1996

Liceo classico statale “A. Manzoni”

Via Orazio 3, Milano

Diploma di Maturità Classica

Capacità e competenze personali

Madrelingua	Italiana				
Altra(e) lingua(e)					
Autovalutazione	Comprensione		Parlato		Scritto
	Ascolto	Lettura	Interazione orale	Produzione orale	
Inglese	Buona	Eccellente	Buona	Buona	Buona

Capacità e competenze sociali	Buona capacità e attitudine al lavoro di gruppo. Buona capacità di comunicazione. Attitudine alla gestione di relazioni interpersonali con figure professionali differenti e complementari (infermieri, assistenti sociali, psicologi, amministrativi) nonché al lavoro in gruppi multiprofessionali e multidisciplinari.
-------------------------------	--

Capacità e competenze organizzative	Dal 2016 ad oggi Referente Formazione Oncologia Medica INT Dal 2021 ad oggi Coordinatrice attività ambulatoriale Oncologia Medica INT
-------------------------------------	--

Capacità e competenze tecniche

Capacità e competenze informatiche	Buona conoscenza dei programmi del pacchetto Microsoft Office (Word, Excel, Power Point) e di Internet
Altre capacità e competenze	• Capacità di gestione di problematiche cliniche e complicanze di pazienti affetti da neoplasie solide in corso di trattamenti chemioterapici e nelle fasi terminali della malattia. • Stesura e conduzione di protocolli di ricerca sponsorizzati e no profit di fase I, II e III come Principal investigator • Attività di ricerca nell'ambito di studi clinici multicentrici internazionali e monocentrici in accordo alle "Good Clinical Practice", con particolare riferimento alla diagnosi e al trattamento del carcinoma renale e prostatico • Stesura e gestione di progetti di ricerca sponsorizzata da enti finanziatori (AIRC; Ministero della Salute)
Patente	B

Ulteriori informazioni

Membro delle seguenti società scientifiche:

- ASCO (American Society of Clinical Oncology)
- ESMO (European Society for Medical Oncology)
- AIOM (Associazione Italiana di Oncologia Medica)
- MeetUro (Italian Network for Research in Urology Oncology)

Partecipazione in qualità di moderatrice e/o relatrice a numerosi congressi nazionali e internazionali

- **17/12/2023: Abilitazione Scientifica Nazionale alle funzioni di Professore Universitario di II Fascia nel settore concorsuale 06/D3-Malattie del Sangue, Oncologia, Reumatologia (valida fino al 17/12/2034)**
- Dal 21/07/21 Membro dell'**Internal Review Board per gli studi clinici di intervento (IRB)** della Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
- Dal 12/2022 membro del Consiglio della Direzione Scientifica della Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
- Membro (esperto clinico) del **comitato etico scientifico Milano Area 3** dal 12/2017 al 01/2020
- Dal 05/19 al 05/21 Segretario gruppo cooperativo Meeturo (Italian Network for Research in Urology Oncology)
- Dal 06/21 ad oggi Consigliere gruppo cooperativo Meeturo
- Dal 2019 ad oggi Estensore linee guida AIOM "tumore del rene"
- Dal 2021 ad oggi Estensore linee guida AIOM "tumore della prostata"
- Progettazione e stesura PDTA per il carcinoma renale e prostatico, Fondazione IRCCS Istituto Nazionale dei Tumori Milano
- PI progetto Ricerca Finalizzata RF-2016-02363001 - Prospective translational study investigating predictors of outcome in metastatic renal cell carcinoma patients treated with Nivolumab (I-Rene trial)
- coPI progetto Ricerca Finalizzata RF-2019-12369602- Collecting Ducts Carcinoma: in depth exploration and biologically driven therapy (CICERONE).

CORSI DI FORMAZIONE:

10/2013: corso GCP (good clinical practice) e successivi retraining

10/2022: corso BLS-D (basic life support-defibrillation) retraining

04/2019: corso ALS (advanced life support)

10/2023: corso ALS (advanced life support)

Allegati PUBBLICAZIONI

Pubblicazioni

1. Procopio G, **Verzoni E**, Mancin M. Caso clinico: Insulinoma del pancreas. Casi clinici in oncologia 11:20-23; Dicembre 2004.
2. Canova S, **Verzoni E**, Procopio G. Caso clinico: carcinoma neuroendocrino (NET) del pancreas con localizzazioni testicolari. Casi clinici in oncologia 14:6-8; Novembre 2005.
3. Procopio G, Ricotta R, Fusi A, Celio L, De Dosso S, Catena L, Ferrari L, Quattrone P, **Verzoni E**, Bajetta E. Neuroendocrine tumors of the larynx: a clinical report and literature review. Tumori, 2006 Jan-Feb; 92(1):72-5
4. **E.Verzoni**, G.Procopio. Editoriale; Sorafenib: un nuovo inibitore delle tirosin-kinasi. Casi Clinici in Oncologia, Num 16, Marzo 2006.
5. **E. Verzoni**, A. Gevorgyan, G.Procopio. Caso clinico: recidiva toracica da carcinoma a cellule chiare del rene. Casi Clinici in Oncologia, Marzo 2006.
6. Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari L, Martinetti A, Platania M, **Verzoni E**, Formisano B, Bajetta R. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low grade and high grade neuroendocrine tumours? Cancer Chemother Pharmacol 2007 Apr; 59 (5):637-42
7. Bajetta E, Procopio G, **Verzoni E**, Catena L, De Dosso S, Platania M, Gevorgyan. Renal cell cancer and sorafenib: skin toxicity and treatment outcome. Tumori 2007 Mar-Apr; 93 (2) 201-3
8. De Dosso S, Bajetta E, Procopio G, Cortinovis D, Buzzoni R, Catena L, Platania M, **Verzoni E**. Pulmonary carcinoid tumours: indolent but not benign. Oncology 2007; 73 (3-4): 162-8
9. Procopio G, **Verzoni E**, Gevorgyan A, Mancin M, Pusceddu S, Catena L, Platania M, Guadalupi V, Martinetti A, Bajetta E. Safety and activity of Sorafenib in different histotypes of advanced renal cell cancer. Oncology 2008: 73; 204-209.
10. Bajetta E, Procopio G, **Verzoni E**. Quadri clinici delle sindromi associate ai NET e loro terapia sintomatica in: La Famiglia dei carcinoidi. pp 31-38, Ed.Masson 2008.
11. Bajetta E, **Verzoni E**, Ferrario E, Dotti K, Gevorgyan A and Celio L. Feasibility study of biweekly capecitabine, oxaliplatin and irinotecan in patients with untreated advanced gastric cancer. Tumori 2009 Jan-Feb; 95 (1): 43-47
12. Bajetta E, Procopio G, Pusceddu S, Pietrantonio F, Milione M, Maccauro M, **Verzoni E**, Guadalupi V, Platania M. From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours. Oncol Rev 2009, 3: 79-87.
13. G.Procopio, **E.Verzoni**, F.Pietrantonio, V.Guadalupi, E.Bajetta. Sorafenib nel trattamento del Carcinoma a cellule renali (RCC); a quale paziente?. Cancer Aging vol 6 n.3 suppl 1 2008 S9-S12

14. Bajetta E, Procopio G, Colombo A, Guadalupi V, **Verzoni E**, Pietrantonio F, Pusceddu S, Manzoni M, Gevorgyan A, Buzzoni R. Sorafenib in hepatocellular carcinoma. *Clinical Medicine Therapeutics* 2009; 1: 277-287
15. Procopio G, **Verzoni E**, Guadalupi V, Bajetta E. Sorafenib nel trattamento del paziente anziano affetto da carcinoma a cellule renali (RCC) in fase avanzata. *Geriatric & Medical Intelligence "Medicina e anziani"* vol18, 2009; 125-130
16. Procopio G, **Verzoni E**, Bajetta E. Feasibility and activity for sequencing targeted therapies for the treatment of advanced renal cell carcinoma. *Med Oncol*, Dec 2009
17. **Verzoni E**. Carcinoma renale metastatico: quale spazio per un trattamento sequenziale? In "Casi clinici: carcinoma a cellule renali". CIC Edizioni Internazionali, 2009.
18. G.Procopio, **E.Verzoni**, R.Iacovelli, V.Guadalupi, E.Bajetta. Sorafenib nel trattamento del carcinoma renale avanzato: risultati dei 2 expanded access program in " Presente e futuro di Sorafenib in oncologia. Accademia Nazionale di Medicina, 2010.
19. G.Procopio, **E.Verzoni**, V.Guadalupi, R.Iacovelli and E.Bajetta. Is it possible to optimize the use of targeted therapies in the treatment of renal cell carcinoma. Letter to the editor. *Tumori*, vol 96, no 5, 2010.
20. G Procopio, **E Verzoni**, S Bracarda, S Ricci, C Sacco, L Ridolfi, C Porta, R Miceli, N Zilembo, E Bajetta. Sorafenib with Interleukin 2 vs sorafenib alone in metastatic renal cell carcinoma the ROSORC trial. *Br J Cancer* 2011, 29
21. Porta C, Procopio G, Cartenì G, Sabbatini R, Bearz A, Chiappino I, Ruggeri EM, Re GL, Ricotta R, Zustovich F, Landi L, Calcagno A, Imarisio I, **Verzoni E**, Rizzo M, Paglino C, Guadalupi V, Bajetta E. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. *BJU* 2011 May 23
22. G. Procopio, **E. Verzoni**, R. Iacovelli, V. Guadalupi, F. Gelsomino and R. Buzzoni. Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. *Expert Rev. Anticancer Ther.* 11(11), 1631–1640 (2011)
23. **Verzoni E**, Lanocita R, Procopio G. Complete Response After Sequential Sunitinib-Sorafenib Treatment In a Patient With Renal Cell Carcinoma: A Case Report. *Clin Genitourin Cancer* 2012 Jan 6.
24. Procopio G, **Verzoni E**, Iacovelli R, Colecchia M, Torelli T, Mariani L. Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. *Clin Exp Nephrol* 2012 Jan 26
25. Procopio G, **Verzoni E**, De Braud F. Re: Camillo Porta, Emiliano Calvo, Miguel A.Climent et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD 1 trial. *Eur Urol* 2012; 61: 826-33.
26. Pietrantonio F, Biondani P, **Verzoni E**, Procopio G. Management of advanced genitourinary tumors. *Tumori* 2012 Mar-Apr; 98 (2): 264-6

27. Biondani P, Procopio G, Pietrantonio F, De Braud F, **Verzoni E**. New perspectives in advanced genitourinary malignancies. Tumori 2012; 98: 267-9
28. Procopio G, **Verzoni E**, Iacovelli R, BIASONI D, Testa I, Porcu L, De Braud F. Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. Br J Cancer 2012 Oct 9; 107(8): 1227-32
29. Procopio G, Sabbatini R, Porta C, **Verzoni E**, Galligioni E, Ortega C. Optimizing further treatment choices in short and long term responders to first line therapy for patients with advanced renal cell carcinoma. Exper Rev Anticancer Ther 2012 Aug; 12(8): 1089-96
30. Procopio G, **Verzoni E**, De Braud F. Targeted therapies and survival: what we can learn from studies in advanced renal cell carcinoma. Oncology 2013; 84(1) 39-42
31. . Procopio G, **Verzoni E**, Testa I, Nicolai N, Salvioni R, Debraud F. Experiences with sorafenib in the treatment of advanced renal cell carcinoma. Ther Adv Urol 2012; 4: 303-13
32. **Verzoni E**, Garanzini E, Procopio G. Complete response in advanced renal cell carcinoma: utopia or real chance? Clin Exp Nephrol 2013; 17: 151-2
33. Grassi P, **Verzoni E**, Mariani L, De Braud F, Coppa J, Mazzaferro V, Procopio G. Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center. Clin Genitourin Cancer 2013; Jun 19.
34. Procopio G, **Verzoni E**, Bracarda S, Ricci S, Sacco C, Ridolfi L, Porta C, Miceli R, Zilembo N, Bajetta E; on behalf of Italian Trials in Medical Oncology (ITMO) group. Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial. Ann Oncol. 2013 Sep 24
35. Procopio G, Grassi P, Testa I, **Verzoni E**, Torri V, Salvioni R, Valdagni R, de Braud F. Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. Am J Clin Oncol 2013. Sep 21.
36. **Verzoni E**, de Braud F, Fabiani F, Grassi P, Testa I, Procopio G. Patient approach in advanced/metastatic renal cell carcinoma: focus on the elderly population and treatment-related toxicity. Future Oncol 2013 Nov 9 (11): 1599-607
37. Iacovelli R, **Verzoni E**, De Braud F, Procopio G. First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profile. Cancer Biol Ther 2013 Nov 19; 15(1)
38. Procopio G, Testa I, Iacovelli R, Grassi P, **Verzoni E**, Garanzini E, Colecchia M, Torelli T, De Braud F. Treatment of collecting duct carcinoma: current status and future perspectives. Anticancer Res 2014 34 (2): 1027-30
39. Iacovelli R, **Verzoni E**, De Braud FM, Procopio G. Study design and clinical evidence in mRCC: can we save axitinib as first line therapy? Cancer Biol Ther 2014 Feb 20; 15 (5)

40. Iacovelli R, Cartenì G, Milella M, Berardi R, Di Lorenzo G, **Verzoni E**, Rizzo M, Santoni M, Procopio G. Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib. *G. Can Urol Assoc J.* 2014 Mar-Apr;8(3-4):E121-5
41. **Verzoni E**, Grassi P, Testa I, Iacovelli R, Biondani P, Garanzini E, De Braud F, Procopio G. Targeted treatments in advanced renal cell carcinoma: focus on axitinib. *Pharmgenomics Pers Med.* 2014 Mar 27;7:107-16. doi: 10.2147/PGPM.S37098. eCollection 2014. Review.
42. Biondani P, **Verzoni E**, Torri V, Porcu L, Grassi P, Testa I, DE Braud F, Procopio G. Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients. *Anticancer Res.* 2014 May;34(5):2395-8.
43. Santoni M, Conti A, Porta C, Procopio G, Sternberg CN, Basso U, De Giorgi U, Bracarda S, Rizzo M, Ortega C, Massari F, Iacovelli R, Derosa L, Masini C, Milella M, Di Lorenzo G, Atzori F, Pagano M, Buti S, De Vivo R, Mosca A, Rossi M, Paglino C, **Verzoni E**, Cerbone L, Muzzonigro G, Falconi M, Montironi R, Burattini L, Santini D, Cascinu S. Sunitinib, pazopanib or sorafenib for the treatment of patients with late-relapsing (>5 years) metastatic renal cell carcinoma. *J Urol.* 2014 Jul 18.
44. Grassi P, **Verzoni E**, Porcu L, Testa I, Iacovelli R, Torri V, Braud Fd, Procopio G. Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. *Future Oncol.* 2014 Jun;10(8):1361-72
45. Procopio G, **Verzoni E**, De Braud F. Butterfly and Renal Cell Cancer: Out of Chaos Comes Order. *J Clin Oncol.* 2014 Jul 28.
46. Testa I, **Verzoni E**, Grassi P, Colecchia M, Panzone F, Procopio G. Response to targeted therapy in urachal adenocarcinoma. *Rare Tumors.* 2014 Dec 9;6(4):5529
47. Iacovelli R, Farcomeni A, Sternberg CN, Carteni' G, Milella M, Santoni M, Cerbone L, Di Lorenzo G, **Verzoni E**, Ortega C, Sabbatini R, Ricotta R, Messina C, Lorusso V, Atzori F, De Vincenzo F, Sacco C, Boccardo F, Valduga F, Massari F, Baldazzi V, Cinieri S, Mosca A, Ruggeri EM, Berruti A, Procopio G. Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma. *J Urol.* 2014 Nov 26
48. Iacovelli R, Sternberg CN, Porta C, **Verzoni E**, Braud Fd, Escudier B, Procopio G. Inhibition of the VEGF/VEGFR Pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. *Curr Drug Targets.* 2015;16(2):164-70
49. Procopio G, Testa I, **Verzoni E**, Iacovelli R, Grassi P, Galli G, De Braud F, Saravia D, Salvioni R. Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies: overall results from a large cohort of patients. *Oncology.* 2014 Nov 4;88(3):133-138
50. Iacovelli R, Santoni M, **Verzoni E**, Grassi P, Testa I, de Braud F, Cascinu S, Procopio G. everolimus and Temsirolimus are not the same second line in metastatic renal cell carcinoma. A systematic Review and meta-analysis of literature data. *Clin Genitourin Cancer.* 2014 Aug 2.

51. **Verzoni E**, Pusceddu S, Buzzoni R, Garanzini E, Damato A, Biondani P, Testa I, Grassi P, Bajetta E, de Braud F, Procopio G. safety profile and treatment response of everolimus in different solid tumors: an observational study. *Future Oncol.* 2014;10(9):1611-7
52. Necchi A, Farè E, Vullo SL, Giannatempo P, Raggi D, Nicolai N, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, **Verzoni E**, Grassi P, Procopio G, Pizzocaro G, Mariani L, Salvioni R. Clinical outcomes of metastatic poor prognosis germ cell tumors: current perspective from a referral center. *Clin Genitourin Cancer* 2015, feb 7.
53. Grassi P, **Verzoni E**, Porcu L, Iacovelli R, de Braud F, Procopio G. Site of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first line sunitinib or sorafenib. *Ther Adv Urol* 2015 apr; 7 (2): 59-68
54. Pantano F, Santoni M, Procopio G, Rizzo M, Iacovelli R, Porta C, Conti A, Lugini A, Milella M, Galli L, Ortega C, Guida FM, Silletta M, Schinzari G, **Verzoni E**, Modica D, Crucitti P, Rauco A, Felici A, Ballatore V, Cascinu S, Tonini G, Carteni G, Russo A, Santini D. The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker? *PLoS One.* 2015 Apr 17;10(4)
55. Platania M, **Verzoni E**, Vitali M. Hyponatremia in cancer patients *Tumori.* 2015 Mar-Apr;101(2):246-8.
56. **Verzoni E**, Grassi P, Montone R, Galli G, Necchi A, Procopio G. TOKIO rationale and protocol: a phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma. *Tumori.* 2015 Jun 20;0(0):0.
57. Zanardi E, **Verzoni E**, Grassi P, Necchi A, Giannatempo P, Raggi D, De Braud F, Procopio G. Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma. *Ther Adv Urol.* 2015 Jun;7(3):152-61
58. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B; Rainbow Group. *Ann Oncol.* 2015 Oct;26(10):2107-13. doi: 10.1093/annonc/mdv315. Epub 2015 Jul 27. Erratum in: *Ann Oncol.* 2016 Feb;27(2):366.
59. Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma. Iacovelli R, Santini D, Rizzo M, Felici A, Santoni M, **Verzoni E**, Masini C, Massari F, Calvani N, Mosca A, Procopio G. *Can Urol Assoc J.* 2015 Jul-Aug;9(7-8):263-7.
60. Treatment of elderly patients with metastatic renal cell carcinoma. Zanardi E, Grassi P, Cavo A, **Verzoni E**, Maggi C, De Braud F, Boccardo F, Procopio G. *Expert Rev Anticancer Ther.* 2016;16(3):323-34.
61. Predicting Molecular Models: Where Are We Going? Ratta R, **Verzoni E**, Grassi P, Niger M, Procopio G. *EBioMedicine.* 2015 Oct 9;2(11):1594-5.

62. Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. Santini D, Santoni M, Conti A, Procopio G, **Verzoni E**, Galli L, di Lorenzo G, De Giorgi U, De Lisi D, Nicodemo M, Maruzzo M, Massari F, Buti S, Altobelli E, Biasco E, Ricotta R, Porta C, Vincenzi B, Papalia R, Marchetti P, Burattini L, Berardi R, Muto G, Montironi R, Cascinu S, Tonini G. *Oncotarget*. 2016 May 31;7(22):33381-90.
63. Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. Grassi P, Doucet L, Giglione P, Grünwald V, Melichar B, Galli L, De Giorgi U, Sabbatini R, Ortega C, Santoni M, Bamias A, **Verzoni E**, Derosa L, Studentova H, Pacifici M, Coppa J, Mazzaferro V, de Braud F, Porta C, Escudier B, Procopio G. *PLoS One*. 2016 Apr 11;11(4):.
64. Predictors of long-term response to abiraterone in patients with metastatic castration-resistant prostate cancer: a retrospective cohort study. **Verzoni E**, De Giorgi U, Derosa L, Caffo O, Boccardo F, Facchini G, Porcu L, De Vincenzo F, Zaniboni A, Chiuri VE, Fratino L, Santini D, Adamo V, De Vivo R, Dinota A, Messina C, Ricotta R, Caserta C, Scavelli C, Susi M, Tartarone A, Surace G, Mosca A, Bruno M, Barni S, Grassi P, Procopio G. *Oncotarget*. 2016 May 19.
65. Adjuvant treatment for renal cell carcinoma: in the long run will we get the same answers? Grassi P, **Verzoni E**, Procopio G. *Expert Rev Anticancer Ther*. 2016 Aug;16(8):803-4.
66. Immunotherapy advances in uro-genital malignancies. Ratta R, Zappasodi R, Raggi D, Grassi P, **Verzoni E**, Necchi A, Di Nicola M, Salvioni R, de Braud F, Procopio G. *Crit Rev Oncol Hematol*. 2016 Sep;105:52-64.
67. Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy. Grassi P, **Verzoni E**, Ratta R, Mennitto A, de Braud F, Procopio G. *Drug Des Devel Ther*. 2016 Jul 5;10:2167-72.
68. Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. **Verzoni E**, Grassi P, Ratta R, Niger M, De Braud F, Valdagni R, Procopio G. *Ther Adv Med Oncol*. 2016 Sep;8(5):323-30. Epub 2016 Jul 5
69. Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. Mennitto A, Grassi P, Ratta R, **Verzoni E**, Prisciandaro M, Procopio G. *Ther Adv Urol*. 2016 Oct;8(5):319-326.
70. Predictors of long-term response to abiraterone in patients with metastatic castration-resistant prostate cancer: a retrospective cohort study. **Verzoni E**, De Giorgi U, Derosa L, Caffo O, Boccardo F, Facchini G, Porcu L, De Vincenzo F, Zaniboni A, Chiuri VE, Fratino L, Santini D, Adamo V, De Vivo R, Dinota A, Messina C, Ricotta R, Caserta C, Scavelli C, Susi M, Tartarone A, Surace G, Mosca A, Bruno M, Barni S, Grassi P, Procopio G. *Oncotarget*. 2016 Jun 28;7(26):40085-40094.

71. Multimodal treatment of advanced renal cancer in 2017. Mennitto A, **Verzoni E**, Grassi P, Ratta R, Fucà G, Procopio G. Expert Rev Clin Pharmacol. 2017 Oct 6:1-8.
72. Castration-naïve metastatic prostate cancer: reshaping old paradigms. Ratta R, Grassi P, Fucà G, **Verzoni E**, Procopio G. Expert Rev Anticancer Ther. 2017 Oct;17(10):879-881. doi: 10.1080/14737140.2017.1374178. Epub 2017 Sep 11..
73. Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma? Grassi P, **Verzoni E**, Ratta R, Porcu L, Prisciandaro M, Mennitto A, Calareso G, de Braud F, Procopio G. Drugs R D. 2017 Aug 11.
74. Everolimus treatment for neuroendocrine tumors: latest results and clinical potential. Pusceddu S, **Verzoni E**, Prinzi N, Mennitto A, Femia D, Grassi P, Concas L, Vernieri C, Lo Russo G, Procopio G. Ther Adv Med Oncol. 2017 Mar;9(3):183-188.
75. Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents. Grassi P, Doucet L, Giglione P, Grünwald V, Melichar B, Galli L, De Giorgi U, Sabbatini R, Ortega C, Santoni M, Bamias A, **Verzoni E**, Derosa L, Studentova H, Porcu L, De Braud F, Porta C, Procopio G. Oncology. 2017;92(5):269-275
76. What advances have been made in immune-therapy for renal cell carcinoma? **Verzoni E**, Grassi P, Ratta R. Future Oncol. 2017 Apr;13(8):665-668.
77. Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience. De Gobbi A, Biasoni D, Catanzaro M, Nicolai N, Piva L, Stagni S, Torelli T, Procopio G, **Verzoni E**, Grassi P, Colecchia M, Paolini B, Spreafico C, Marchianò A, Salvioni R. Tumori. 2017 Jan 7:0.
78. Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice. Grassi P, **Verzoni E**, Mennitto A, Procopio G. Transl Androl Urol. 2016 Dec;5(6):974-976.
79. Does F-18 FDG-PET still play a role in metastatic renal cell carcinoma? Mennitto A, Grassi P, **Verzoni E**, Ratta R, Procopio G. J Med Imaging Radiat Oncol. 2017 Apr;61(2):250-251.
80. Treatment of advanced renal cell carcinoma: recent advances and current role of immunotherapy, surgery, and cryotherapy. Mennitto A, **Verzoni E**, Calareso G, Spreafico C, Procopio G. Tumori. 2017 Jan 21;103(1):15-21.
81. TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery. **Verzoni E**, Ratta R, Grassi P, Salvioni R, Stagni S, Montone R, Fucà G, Cappelletti V, Reduzzi C, De Giorgi U, Procopio G. Tumori. 2017 Nov 29:0

82. Combination therapies for patients with metastatic renal cell carcinoma. Procopio G, Ratta R, de Braud F, **Verzoni E**. Lancet Oncol. 2018 Mar;19(3):281-283.
83. Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world Analysis. Ratta R, **Verzoni E**, Di Maio M, Grassi P, Colecchia M, Fucà G, de Braud F, Procopio G. Clin Genitourin Cancer. 2018 Feb 5
84. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. Procopio G, Prisciandaro M, Iacovelli R, Cortesi E, Fornarini G, Facchini G, Carteni G, Sabbatini R, Del Bene G, Galli L, Caserta C, Multari AG, Bregni M, Massari F, Buti S, De Giorgi U, Zustovich F, Milella M, Calabrò F, Mancini ML, Tortora G, Vernieri C, Santini D, Sorarù M, Ricotta R, Masini C, Tucci M, Fedeli SL, Ortega C, Mecozzi A, Ratta R, Sternberg CN, **Verzoni E**. Clin Genitourin Cancer. 2018 Aug;16(4):e945-e951. doi: 10.1016/j.clgc.2018.03.014. Epub 2018 Apr 19.
85. Management of Metastatic Collecting Duct Carcinoma: An Encouraging Result in a Patient Treated With Cabozantinib. Mennitto A, **Verzoni E**, Peverelli G, Alessi A, Procopio G. Clin Genitourin Cancer. 2018 Jun;16(3):e521-e523.
86. Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program. Maines F, De Giorgi U, Procopio G, Facchini G, Fratino L, Sabbatini R, Gasparro D, Basso U, Mosillo C, Campadelli E, Massari F, Sava T, Sirotova S, Messina C, Scagliarini S, Conteduca V, **Verzoni E**, Rossetti S, Vecchia A, Kinspergher S, Caffo O. Future Oncol. 2018 Nov;14(26):2691-2699. doi: 10.2217/fon-2018-0113. Epub 2018 Sep 12.
87. INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDia study. Bersanelli M, Giannarelli D, Castrignanò P, Fornarini G, Panni S, Mazzoni F, Tiseo M, Rossetti S, Gambale E, Rossi E, Papa A, Cortellini A, Lolli C, Ratta R, Michiara M, Milella M, De Luca E, Sorarù M, Mucciarini C, Atzori F, Banna GL, La Torre L, Vitale MG, Massari F, Rebuzzi SE, Facchini G, Schinzari G, Tomao S, Bui S, Vaccaro V, Procopio G, De Giorgi U, Santoni M, Ficorella C, Sabbatini R, Maestri A, Natoli C, De Tursi M, Di Maio M, Rapacchi E, Pireddu A, Sava T, Lipari H, Comito F, **Verzoni E**, Leonardi F, Buti S. Immunotherapy. 2018 Oct;10(14):1229-1239..
88. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. **Verzoni E**, Carteni G, Cortesi E, Giannarelli D, De Giglio A, Sabbatini R, Buti S, Rossetti S, Cognetti F, Rastelli F, Sobrero A, Turci D, Sternberg CN, Porta C, Cappuzzo F, Tortora G, Tassinari D, Panni S, Pazzola A, Surico G, Raimondi A, De Giorgi U, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program group. J Immunother Cancer. 2019 Apr 3;7(1):99.

89. Collecting Ducts Carcinoma: an orphan disease. Literature overview and future perspectives. Pagani F, Colecchia M, Sepe P, Apollonio G, Claps M, **Verzoni E**, de Braud F, Procopio G. Cancer Treat Rev. 2019 Sep;79:101891
90. Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. Procopio G, Apollonio G, Cognetti F, Miceli R, Milella M, Mosca A, Chiuri VE, Bearz A, Morelli F, Ortega C, Atzori F, Donini M, Ratta R, Raimondi A, Claps M, Martinetti A, Capitanio U, de Braud FG, Cappelletti V, **Verzoni E**. Eur Urol Oncol. 2019 Sep 18.
91. Should we use combination therapy for all advanced renal cell carcinoma? Procopio G, Sepe P, Claps M, de Braud F, **Verzoni E**. Lancet Oncol. 2019 Aug 16. pii: S1470-2045(19)30518-2
92. Do biomarkers play a predictive role for response to novel immunotherapeutic agents in metastatic renal cell carcinoma? Raimondi A, Sepe P, Claps M, **Verzoni E**, Procopio G. Expert Opin Biol Ther. 2019 Aug 6:1-4.
93. Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group. Procopio G, Pignata S, Altavilla A, Attademo L, De Lisi D, **Verzoni E**, De Giorgi U, Santini D. Future Oncol. 2019 Aug;15(22):2657-2666.
94. Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience. Sepe P, **Verzoni E**, Miodini P, Claps M, Ratta R, Martinetti A, Mennitto R, Sottotetti E, Procopio G, Cappelletti V, Daidone MG. Cancers (Basel). 2019 Jul 13;11(7).
95. Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population. Peverelli G, Raimondi A, Ratta R, **Verzoni E**, Bregni M, Cortesi E, Cartenì G, Fornarini G, Facchini G, Buti S, Galli L, Tucci M, Prisciandaro M, Procopio G. Clin Genitourin Cancer. 2019 Aug;17(4):291-298.
96. The role of metastasectomy in advanced renal cell carcinoma. Apollonio G, Raimondi A, **Verzoni E**, Claps M, Sepe P, Pagani F, Ratta R, Montorsi F, De Braud FGM, Procopio G. Expert Rev Anticancer Ther. 2019 Jul;19(7):603-611.
97. The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice.

Raimondi A, Randon G, Sepe P, Claps M, **Verzoni E**, de Braud F, Procopio G. Int J Mol Sci. 2019 Aug 30;20(17)

98. Collecting ducts carcinoma: An orphan disease. Literature overview and future perspectives. Pagani F, Colecchia M, Sepe P, Apollonio G, Claps M, **Verzoni E**, de Braud F, Procopio G. Cancer Treat Rev. 2019 Sep;79:101891. doi: 10.1016/j.ctrv.2019.101891. Epub 2019 Aug 27. Review.
99. Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. Procopio G, Apollonio G, Cognetti F, Miceli R, Milella M, Mosca A, Chiuri VE, Bearz A, Morelli F, Ortega C, Atzori F, Donini M, Ratta R, Raimondi A, Claps M, Martinetti A, Capitanio U, de Braud FG, Cappelletti V, **Verzoni E**. Eur Urol Oncol. 2019 Nov;2(6):699-707.
100. The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells. Reduzzi C, Vismara M, Gerratana L, Silvestri M, De Braud F, Raspagliesi F, **Verzoni E**, Di Cosimo S, Locati LD, Cristofanilli M, Daidone MG, Cappelletti V. Semin Cancer Biol. 2019 Oct 15. pii: S1044-579X(19)30170-1.
101. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Rini BI, Pal SK, Escudier BJ, Atkins MB, Hutson TE, Porta C, **Verzoni E**, Needle MN, McDermott DF. Lancet Oncol. 2020 Jan;21(1):95-104.
102. Post-surgical Regression of Thoracic Metastases After Salvage Lobectomy for Recurrent Renal Cell Carcinoma. Stanzi A, **Verzoni E**, Ruggirello M, Rolli L, Pastorino U. Clin Genitourin Cancer. 2019 Dec 4. pii: S1558-7673(19)30372-6
103. Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. Santoni M, Heng DY, Bracarda S, Procopio G, Milella M, Porta C, Matrana MR, Carteni G, Crabb SJ, De Giorgi U, Basso U, Masini C, Calabrò F, Vitale MG, Santini D, Massari F, Galli L, Fornarini G, Ricotta R, Buti S, Zucali P, Caffo O, Morelli F, Carrozza F, Martignetti A, Gelibter A, Iacovelli R, Mosca A, Atzori F, Vau N, Incorvaia L, Ortega C, Scarpelli M, Lopez-Beltran A, Cheng L, Paolucci V, Graham J, Pierce E, Scagliarini S, Sepe P, **Verzoni E**, Merler S, Rizzo M, Sorgentoni G, Conti A, Piva F, Cimadamore A, Montironi R, Battelli N. Cancers (Basel). 2019 Dec 30;12(1).
104. Current Understanding of Urachal Adenocarcinoma and Management Strategy. Claps M, Stellato M, Zattarin E, Mennitto A, Sepe P, Guadalupi V, Mennitto R, de Braud FGM, **Verzoni E**, Procopio G. Curr Oncol Rep. 2020 Jan 27;22(1):9.
105. Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDia study. Bersanelli M, Buti S, Banna GL, De Giorgi U, Cortellini A, Rebuzzi SE, Tiseo M, Fornarini G, Mazzoni F, Panni S, Tursi M, Marino PD, Rossetti S, Rossi E, Tomao S, Luca E, Sorarù M, Mucciarini C, Atzori F, Torre L, Vitale MG, Martelli V, Sepe P,

Mollica V, Vaccaro V, Schinzari G, Ficorella C, Massari F, Maestri A, Sabbatini R, Sava T, Maio MD, **Verzoni E**, Procopio G, Giannarelli D. Immunotherapy. 2020 Feb;12(2):151-159.

106. Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to Progression. Cappelletti V, **Verzoni E**, Ratta R, Vismara M, Silvestri M, Montone R, Miodini P, Reduzzi C, Claps M, Sepe P, Daidone MG, Procopio G. Int J Mol Sci. 2020 Feb 21;21(4).
107. Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori. Raimondi A, Sepe P, Claps M, Maccauro M, Aliberti G, Pagani F, Apollonio G, Randon G, Peverelli G, Seregini E, **Verzoni E**, Procopio G. Tumori. 2020 Mar 2
108. Angiogenesis and Immunity in Renal Carcinoma: Can We Turn an Unhappy Relationship into a Happy Marriage? Mennitto A, Huber V, Ratta R, Sepe P, de Braud F, Procopio G, Guadalupi V, Claps M, Stellato M, Daveri E, Rivoltini L, **Verzoni E**. J Clin Med. 2020 Mar 28;9(4).
109. Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial. Porta C, **Verzoni E**, Zai S, Messina C, Ferrari V, Gri N, Procopio G. Tumori. 2020 May
110. Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes. Claps M, Mennitto A, Guadalupi V, Sepe P, Stellato M, Zattarin E, Gillessen SS, Sternberg CN, Berruti A, De Braud FGM, **Verzoni E**, Procopio G. Cancer Treat Rev. 2020 Aug;88.
111. Radical metastasectomy followed by sorafenib versus observation in patients with clear cell renal cell carcinoma: extended follow-up of efficacy results from the randomized phase II RESORT trial. Mennitto A, **Verzoni E**, Cognetti F, Miceli R, Milella M, Mosca A, Chiuri VE, Bearz A, Morelli F, Ortega C, Atzori F, Donini M, Claps M, Guadalupi V, Sepe P, Cappelletti V, de Braud FG, Procopio G. Expert Rev Clin Pharmacol. 2021 Jan 31:1-8
112. Outcomes of systemic targeted therapy in recurrent RCC Renal Cell Carcinoma treated with adjuvant sunitinib. de Velasco G, Ruiz-Granados Á, Reig O, Massari F, Climent Duran MA, **Verzoni E**, Graham J, Llarena R, De Tursi M, Donskov F, Iglesias C, Pandha HS, Del Muro XG, Procopio G, Oudard S, Castellano D, Albiges L. BJU Int. 2021 Feb 6
113. Integrated transcriptional-phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients. Rinchai D, **Verzoni E**, Huber V, Cova A, Squarcina P, De Cecco L, de Braud F, Ratta R, Dugo

114. Characteristics and treatment challenges of non clear cell renal cell carcinoma. Sepe P, Ottini A, Pircher CC, Franza A, Claps M, Guadalupi V, **Verzoni E**, Procopio G. Cancers (Basel). 2021 Jul 28;13(15):3807.
115. Biomarker-driven immunotherapy for precision medicine in prostate cancer. Ottini A, Sep P, Beninato T, Claps M, Guadalupi V, **Verzoni E**, Giannatempo P, Baciarello G, de Braud F, Procopio G. Per Med 2022 Jan
116. Combination therapy in renal cell carcinoma: the best choice for every patient? Rossi E, Bersanelli M, Gelibter AJ, Borsellino N, Caserta C, Doni L, Maruzzo M, Mosca A, Pisano C, **Verzoni E**, Zucali PA. Curr Oncol Rep 2021 Nov 8;23 (12):147
117. Influenza vaccine indication during therapy with immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIA 2). Bersanelli M, Giannarelli D, De Giorgi U, Pignata S, Di Maio M, Clemente A, Verzoni E, Buti S et al FICOG group (Federation of Italian cooperative Oncology groups). J Immunother Cancer 2021 May; 9 (5)
118. Effects of cabozantinib on bone turnover markers in real world metastatic renal cell carcinoma. Ratta R, Verzoni E, Mennitto A, Pantano F, Martinetti A, Raimondi A, Sepe P, Sottotetti E, Mennitto R, Morelli D, Santini D, de Braud F, Procopio G. Tumori 2021 Dec; 107 (6): 542-549.
119. Safety and efficacy of tivozanib in first-line mRCC: a multicenter compassionate use study (Meet-uro 16). Basso U, Procopio G, Fornarini G, Massari F, Bearz A, Fratino L, Milella M, Bassanelli M, Ermacora P, Bimbatti D, **Verzoni E**, Rizzo M, Porta C. Oncology 2021; 99 (12): 747-755
120. Integrative Transcriptomic Analysis reveals distinctive molecular traits and novel subtypes of collecting duct carcinoma. Gargiuli C, Sepe P, Tessari A, Sheets T, Colecchia M, de Braud F, Procopio G, Sensi M, **Verzoni E**, Dugo M. Cancers 2021 Jun 10; 13 (12) 2903
121. Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). Mennitto A, Zattarin E, Di Maio M, Bimbatti D, De Giorgi U, Santini D, Casadei C, Sorarù M, Messina C, Mucciarini C, Di Lorenzo G, Roviello G, Buttigliero C, Stellato M, Sepe P, Claps M, Guadalupi V, Ottini A, Pignata S, de Braud F, **Verzoni E**, Procopio G. Expert Rev Anticancer Ther 2022 Jan (1): 115-121.

122. MDM2 gene amplification as selection tool for innovative targeted approaches in PDL1 positive or negative muscle-invasive urothelial bladder carcinoma. Brunelli M, Tafuri A, Cima L, Cerruto M, Milella M, Zivi A, Buti S, Bersanelli M, Fornarini G, Vellone VG, Rebuzzi S, Procopio G, **Verzoni E** et al, Antonelli A. J Clin Pathol 2022 Jan; 75 (1): 39-44.
123. Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations. Iacovelli R, Ciccarese C, Procopio G, Astore S, Cannella MA, Maratta MG, Rizzo M, **Verzoni E**, Porta C, Tortora G. Cancer Treat Rev. 2022 Apr; 105
124. Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma: Results of the BONSAI Trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study). Procopio G, Sepe P, Claps M, Buti S, Colecchia M, Giannatempo P, Guadalupi V, Mariani L, Lalli L, Fucà G, de Braud F, **Verzoni E**. JAMA Oncol. 2022 Apr 14
125. Biomarker-driven immunotherapy for precision medicine in prostate cancer.
Ottini A, Sepe P, Beninato T, Claps M, Guadalupi V, **Verzoni E**, Giannatempo P, Baciarello G, de Braud F, Procopio G. Per Med. 2022 Jan;19(1):51-66. doi: 10.2217/pme-2021-0079. Epub 2021 Dec 7.
126. Unexpected Detection of Skeletal Muscle Renal Cell Carcinoma Metastasis With 99mTc-EDDA/HYNIC-Tyr3-Octreotide (Tektrotyd) Scan. Fuoco V, Barisella M, Lorenzoni A, **Verzoni E**, Maccauro M.
Clin Nucl Med. 2022 May 27.
127. Achieving Consensus for Management of Hormone-Sensitive, Low-Volume Metastatic Prostate Cancer in Italy.
Verzoni E, Pappagallo G, Alongi F, Arcangeli S, Francolini G, Galanti D, Galli L, Maruzzo M, Rossetti S, Siepe G, Triggiani L, Zucali PA, D'Angelillo RM. Curr Oncol. 2022 Jun 28;29(7):4578-4586.
129. The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs. Del Re M, Crucitta S, Paolieri F, Cucchiara F, **Verzoni E**, Bloise F, Ciampi R, Mercinelli C, Capuano A, Sportiello L, Martinetti A, Procopio G, Galli L, Porta C, Bracarda S, Danesi R. J Transl Med. 2022 Aug 16;20(1):371.
128. Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. Terbuch A, Posch F, Bauernhofer T, Jost PJ, Partl R, Stranzl-Lawatsch H, Baciarello G, Fizazi K,

Giannatempo P, **Verzoni E**, Sweeney C, Ravi P, Tran B, Basso U, White J, Vincenzi B, Oing C, Cutuli HJ, Dieckmann KP, Gamulin M, Chovanec M, Fankhauser CD, Heidenreich A, Mohamad O, Thibault C, Fischer S, Gillessen S; International Germ Cell Cancer Collaborative Group. Int J Radiat Oncol Biol Phys. 2022 Jul 15;113(4):825-832.

129. Validation of a Novel Three-Dimensional (*3D Fusion*) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. Brunelli M, Martignoni G, Malpeli G, Volpe A, Cima L, Raspollini MR, Barbareschi M, Tafuri A, Masi G, Barzon L, Ammendola S, Villanova M, Cerruto MA, Milella M, Buti S, Bersanelli M, Fornarini G, Rebuzzi SE, Vellone VG, Gaggero G, Procopio G, **Verzoni E**, Bracarda S, Fanelli M, Sabbatini R, Passalacqua R, Perrucci B, Giganti MO, Donini M, Panni S, Tucci M, Prati V, Ortega C, Calìo A, Eccher A, Alongi F, Pappagallo G, Iacovelli R, Mosca A, Umari P, Montagnani I, Gobbo S, Atzori F, Munari E, Maruzzo M, Basso U, Pierconti F, Patriarca C, Colombo P, Lapini A, Conti G, Salvioni R, Bollito E, Cossarizza A, Massari F, Rizzo M, Franco R, Zito-Marino F, Aberasturi Plata Y, Galuppini F, Sbaraglia M, Fassan M, Dei Tos AP, Colecchia M, Moch H, Scaltriti M, Porta C, Delahunt B, Giannarini G, Bortolus R, Rescigno P, Banna GL, Signori A, Obispo MAL, Perris R, Antonelli A. J Pers Med. 2022 Apr 30;12(5):727

130. Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib. Iacovelli R, Ciccarese C, Maruzzo M, Atzori F, Galli L, Scagliarini S, Massari F, **Verzoni E**, Cannella A, Maratta MG, Caserta C, Bimbatti D, Deppieri FM, Dessi M, Paolieri F, Riccardi F, Bracarda S, De Giorgi U, Basso U, Tortora G, Procopio G. Clin Genitourin Cancer. 2022 Oct;20(5):498.e1-498.e9.

131. Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3. Meza L, McDermott DF, Escudier B, Hutson TE, Porta C, **Verzoni E**, Atkins MB, Kasturi V, Pal SK, Rini B. Oncologist. 2022 Dec 28

132. Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer. Zengin ZB, Pal SK, McDermott DF, Escudier B, Hutson TE, Porta C, **Verzoni E**, Atkins MB, Kasturi V, Rini B. Clin Genitourin Cancer. 2022 Dec;20(6):553-557.

133. Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy. Bottiglieri A, Sepe P, Stellato M, Pircher C, Fotia G, Leone AG, Guadalupi V, Claps M, Giannatempo P, **Verzoni E**, Procopio G. Cancer Manag Res. 2022 Oct 21;14:3071-308
134. The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma Sebastiano Buti , Chiara Tommasi , Giulia Scartabellati , Ugo De Giorgi , Nicole Brighi , Sara Elena Rebuzzi , Silvia Puglisi , Orazio Caffo , Stefania Kinspergher , Alessia Mennitto , Carlo Cattrini , Matteo Santoni , **Elena Verzoni** , Alessandro Rametta , Marco Stellato , Andrea Malgeri , Giandomenico Roviello , Massimo de Filippo , Alessio Cortellini , Melissa Bersanelli Anticancer Drugs 2023 Jan 1;34(1):178-186
135. Gender Difference in side Effects of Immunotherapy: a possible clue to optimize cancer treatment (G-DEFINER): study protocol of an observational prospective multicenter study.
Miceli R, Eriksson H, Lo Russo G, Alfieri S, Moksnes Bjaanæs M, Pietrantonio F, De Cecco L, Prelaj A, Proto C, Franzén J, McDonnell D, Berenguer Pina JJ, Beninato T, Mazzeo L, Giannatempo P, **Verzoni E**, Crown J, Helland Å, Eustace A. Acta Oncol. 2024 Apr 21;63:213-219.
136. A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study). Sepe P, Procopio G, Pircher CC, Basso U, Caffo O, Cappelletti V, Claps M, De Giorgi U, Fratino L, Guadalupi V, Miodini P, De Marco C, Perrucci B, Mennitto A, Santini D, Spina F, Stellato M, de Braud F, **Verzoni E**. Ther Adv Med Oncol. 2024 Jan 22
137. Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27. Stellato M, Buti S, Maruzzo M, Bassanelli M, Bersanelli M, Napoli MD, Dionesi M, Fanelli M, Filippi R, Fotia G, Galli L, Grillone F, Maffezzoli M, Maiorano BA, Nasso C, Rebuzzi SE, Lalli L, Roviello G, Sorarù M, Vincenzi B, Procopio G, **Verzoni E**. Clin Genitourin Cancer. 2024 Jun;22(3):102078
138. Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer. De Santis M, Breijo SM, Robinson P, Capone C, Pascoe K, Van Sanden S, Hashim M, Trevisan M, Daly C, Reitsma F, van Beekhuizen S, Ruan H, Heeg B, **Verzoni E**. Adv Ther. 2024 Jul 3.

139. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial. Beckermann KE, Asnis-Alibozek AG, Atkins MB, Escudier B, Hutson TE, Kasturi V, McDermott DF, Pal SK, Porta C, Rini BI, **Verzoni E**. *Oncologist*. 2024 Mar 4;29(3):254-262
140. Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study. Iacovelli R, Ciccarese C, Buti S, Zucali PA, Fantinel E, Bimbatti D, **Verzoni E**, Accettura C, Bonomi L, Buttigliero C, Fornarini G, Pipitone S, Atzori F, Masini C, Massari F, Primi F, Strusi A, Giudice GC, Perrino M, Maruzzo M, Milella M, Giannarelli D, Brunelli M, Procopio G, Tortora G. *Eur Urol*. 2024 Mar 22:S0302-2838(24)02132-8
141. Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis. Maiorano BA, De Giorgi U, **Verzoni E**, Maiello E, Procopio G, Conteduca V, Di Maio M; MeetURO group. *Target Oncol*. 2024 Jan;19(1):1-11
142. CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma. Barthélémy P, Dutailly P, Qvick B, Perrot V, **Verzoni E**. *Future Oncol*. 2024 Apr;20(13):811-819.
143. Impact of Prior Cyto-reductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial. Grimm MO, Oya M, Choueiri TK, Motzer RJ, Schmidinger M, Quinn DI, Gravis-Mescam G, **Verzoni E**, Van den Eertwegh AJM, di Pietro A, Mariani M, Wang J, Thomaidou D, Albiges L. *Eur Urol*. 2024 Jan;85(1):8-12
144. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours. Celsa C, Cabibbo G, Fulgenzi CAM, Scheiner B, D'Alessio A, Manfredi GF, Nishida N, Ang C, Marron TU, Saeed A, Wietharn B, Pinter M, Cheon J, Huang YH, Lee PC, Phen S, Gampa A, Pillai A, Vivaldi C, Salani F, Masi G, Roehlen N, Thimme R, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, Kudo M, Rimassa L, Singal AG, El Tomb P, Ulahannan S, Parisi A, Chon HJ, Hsu WF, Stefanini B, **Verzoni E**, Giusti R, Vecchia A, Catino A, Aprile G, Guglielmini PF, Di Napoli M, Ermacora P, Antonuzzo L, Rossi E, Verderame F, Zustovich F, Ficorella C, Di Pietro FR, Battelli N, Negrini G, Grossi F, Bordonaro R, Pipitone S, Banzi M, Ricciardi S, Laera L, Russo A, De Giorgi U, Cavanna L, Sorarù M, Montesarchio V, Bordi P, Brunetti L, Pinto C, Bersanelli M, Cammà C, Cortellini A, Pinato DJ. *J Hepatol*. 2024 Mar;80(3):431-442

145. Gender Difference in side Effects of Immunotherapy: a possible clue to optimize cancer treatment (G-DEFINER): study protocol of an observational prospective multicenter study. Miceli R, Eriksson H, Lo Russo G, Alfieri S, Moksnes Bjaanæs M, Pietrantonio F, De Cecco L, Prelaj A, Proto C, Franzén J, McDonnell D, Berenguer Pina JJ, Beninato T, Mazzeo L, Giannatempo P, **Verzoni E**, Crown J, Helland Å, Eustace A. *Acta Oncol.* 2024 Apr 21;63:213-219.
146. Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer. Del Re M, Crucitta S, Brighi N, Kinspergher S, Mercinelli C, Rizzo M, Conteduca V, Rebuzzi SE, Beninato T, Venturi G, Doni L, **Verzoni E**, Puglisi S, Landriscina M, Porta C, Manfredi F, Caffo O, De Giorgi U, Fogli S, Danesi R. *Clin Genitourin Cancer.* 2024 Oct;22(5):102147
147. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, **Verzoni E**, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Schutz FA, Park SH, Nosov DA, Porta C, Lee JL, Garcia-Del-Muro X, Biscaldi E, Mannehh Kopp R, Oya M, He L, Wang A, Perini RF, Vickery D, Albiges L, Rini B; LITESPARK-005 Investigators. *N Engl J Med.* 2024 Aug 22;391(8):710-721.
148. Italian Registry on Rare Urological Tumors (Meet-URO-23): The First Analysis on Collecting Duct Carcinoma of the Kidney. Giudice GC, Maruzzo M, **Verzoni E**, Procopio G, Bimbatti D, Sepe P, Maines F, Grillone F, Cavo A, Santoni M, Cordua N, Pecoraro G, Prati V, Napoli MD, Ollari E, Caruso G, Simoni N, Campobasso D, Buti S. *Clin Genitourin Cancer.* 2024 Oct;22(5):102186.
149. Hot topics in genitourinary cancers: A multidisciplinary discussion on state-of-the-art and latest developments among international experts and patient advocacy. Rametta A, Ambrosini P, Cavalli C, Gusmaroli E, Claps M, Giannatempo P, Guadalupi V, Stellato M, **Verzoni E**, De Braud FMG, Procopio G. *Tumori.* 2024 Dec;110(6):410-415.
150. Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial. Choueiri TK, Kuzel TM, Tykodi SS, **Verzoni E**, Kluger H, Nair S, Perets R, George S, Gurney H, Pachynski RK, Folefac E, Castonguay V, Lee CH, Vaishampayan U, Miller WH Jr, Bhagavatheeswaran P, Wang Y, Gupta S, DeSilva H, Lee CW, Escudier B, Motzer RJ. *ESMO Open.* 2024 Dec;9(12):104073.

151. A Prospective Non-interventional Real-World Study of cabozantinib in Pretreated Patients With Advanced Renal Cell Carcinoma Refractory to Vascular Endothelial Growth Factor-Targeted Therapy (CASSIOPE). Staehler M, Basso U, Eymard JC, Barthelemy P, Bigot P, Laramas M, Rink M, Suarez C, Guillot A, Bedke J, Hamberg P, De Vivo R, Gajate P, Lázaro-Quintela M, Rastogi P, Perrot V, Qvick B, Dutailly P, **Verzoni E**, Procopio G. Clin Genitourin Cancer. 2024 Nov 30;23(1):102285
- 152 Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study. Zugman M, McDermott DF, Escudier BJ, Hutson TE, Porta C, **Verzoni E**, Atkins MB, Rini B, Pal SK. Oncologist. 2025 Feb 6;30(2)
153. Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial. Powles T, Choueiri TK, Albiges L, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, **Verzoni E**, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Rizzo M, Shinde R, Saretsky TL, He L, Perini RF, Vickery D, Rini B. Lancet Oncol. 2025 Apr;26(4):491-502. doi: 10.1016/S1470-2045(25)00032-4. Epub 2025 Mar 17.
154. Pathological Complete Response in Metastatic Renal Cell Carcinoma Patients Treated With Cabozantinib Plus Nivolumab. Case Series and Literature Review. Stellato M, Rota S, Claps M, Guadalupi V, Rametta A, Fotia G, Barella M, **Verzoni E**, Procopio G. Clin Genitourin Cancer. 2025 Mar 7;23(3):

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della L. 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, secondo quanto previsto dalla Legge 675/96 del 31 dicembre 1996.

I

In Fede

Elena Verzoni